Xynomic Pharmaceuticals
Shanghai
About Xynomic Pharmaceuticals
Xynomic Pharma focuses on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building, and exiting successful US-China biopharmaceutical companies.Xynomic Pharma aims to build a comprehensive clinical and pre-clinical stage oncology pipeline targeting cancers with high prevalence in China, US and rest of the world. Xynomic Pharma leverages global resources, enabling the company to develop drugs in a cost and time-efficient manner.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $4.8M
- Funding stage: IPO
- Last round: Series B (Jun 2018)
- Ticker: nyse:XYN
- Website: xynomicpharma.comen506-11
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Medical, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/xynomic-pharmaceuticals-2221807 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.